Statistik Asas
| CIK | 1737523 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioNexus Gene Lab Corp.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-41750 BioNexus Gene Lab Corp. |
|
| August 18, 2025 |
Form of Non-Qualified Stock Option Agreement EXHIBIT 10.8 BIONEXUS GENE LAB CORP. FORM OF NON‑QUALIFIED STOCK OPTION AGREEMENT This Non‑Qualified Stock Option Agreement (this “Agreement”) is made as of the Grant Date specified in Exhibit A (Grant Summary) by and between BioNexus Gene Lab Corp., a Wyoming corporation (the “Company”), and the individual identified in Exhibit A (the “Optionee”), pursuant to and in furtherance of a standalone co |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2025 PART I: REGISTRANT INFORMATION Full Name of Registrant: BioNexus Gene Lab Corp. Address of Principal Executive Office: Unit A-28-7, Tower A, Menara UOA Bangsar, No. 5 Jln |
|
| July 30, 2025 |
BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new EXHIBIT 99.1 FOR IMMEDIATE RELEASE BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology Kuala Lumpur, Malaysia – July 30th, 2025 – BioNexus Gene Lab Corp. (“BGLC”, Nasdaq: BGLC) and Fidelion Diagnostics Pte Ltd, a Singaporean company (“Fidelion”) today announced the signing of a term sheet for a strategic, cross‑equity |
|
| July 30, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2025 BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commission (IRS Employer of Incorp |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (Commi |
|
| June 23, 2025 |
The Service Contract between the Company and Ms. Chong Set Fui (Angeline) EXHIBIT 10.7 MRNA Scientific Sdn Bhd A-28-07 Menara UOA Bangsar No. 5 Jalan Bangsar Utama 1 Kuala Lumpur, Malaysia 59000 PRIVATE & CONFIDENTIAL [BY HAND] 17 June 2025 Chong Set Fui (Angeline) Dear Mrs. Chong, LETTER OF EMPLOYMENT – CHIEF FINANCIAL OFFICER We are pleased to offer you employment in MRNA SCIENTIFIC SDN BHD (the “Company”) according to the following terms and conditions: 1. JOB TITLE |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-41750 BioNexus Gene Lab Corp. |
|
| April 30, 2025 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness Kuala Lumpur, Malaysia - April 30, 2025 - BioNexus Gene Lab Corp. (Nasdaq: BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Mark |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2025 BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commission (IRS Employer of Incor |
|
| April 29, 2025 |
Policy Relating to Recovery of Erroneously Awarded Compensation* EXHIBIT 97 BIONEXUS GENE LAB CORP. (the “Company”) Policy on Recovery of Erroneously Awarded Compensation ("Clawback Policy") 1. Purpose This Policy is established to comply with Section 10D of the Securities Exchange Act of 1934 and Rule 10D-1 thereunder, as well as Nasdaq Listing Rule 5608. The Policy provides for the recovery of certain incentive-based compensation awarded to current and former |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. |
|
| April 15, 2025 |
Articles of Amendment filed with the Wyoming Secretary of State on April 1, 2025. EXHIBIT 3.7 |
|
| April 15, 2025 |
Director Offer Letter by and between the Registrant and Muhammad Azrul bin Abdul Hamid EXHIBIT 10.4 March 26, 2024 Re: Director Offer Letter – Muhammad Azrul bin Abdul Hamid Dear Mr. Muhammad Azrul bin Abdul Hamid: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background and experience will be a significant asset to the Company and we look forward to your participation as a Dir |
|
| April 15, 2025 |
Director Offer Letter by and between the Registrant and Jook Yuen Low EXHIBIT 10.5 November 5, 2024 Re: Director Offer Letter – Jook Yuen Low Dear Ms. Jook Yuen Low: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background and experience will be a significant asset to the Company and we look forward to your participation as a Director in the Company. Should you |
|
| April 15, 2025 |
Bylaws of the Registrant, as currently in effect EXHIBIT 3.2 BYLAWS OF BIONEXUS GENE LAB CORP. ARTICLE I (Offices) Section 1.1. Principal Office. The principal office of the corporation shall be located at such place as the board shall designate. The corporation may have such other offices and places of business, either within or outside of Wyoming, as the board may designate or as the affairs of the corporation may require. Section 1.2. Registe |
|
| April 15, 2025 |
Director Offer Letter by and between the Registrant and Su-Leng Tan Lee EXHIBIT 10.3 March 26, 2024 Re: Director Offer Letter – Su-Leng Tan Lee Dear Mr. Tan Lee: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background and experience will be a significant asset to the Company and we look forward to your participation as a Director in the Company. Should you choos |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41750 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| April 15, 2025 |
Articles of Amendment filed with the Wyoming Secretary of State on February 11, 2025. EXHIBIT 3.6 |
|
| April 15, 2025 |
List of Subsidiaries of the Registrant EXHIBIT 21 Subsidiaries MRNA Scientific Sdn. Bhd., a Malaysian corporation Chemrex Corporation Sdn. Bhd., a Malaysian corporation |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2025 BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commission (IRS Employer of Incorp |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2025 BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commission (IRS Employer of Incorp |
|
| April 3, 2025 |
Articles of Amendment filed with the Wyoming Secretary of State on April 1, 2025. EXHIBIT 3.7 |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2024 PART I: REGISTRANT INFORMATION Full Name of Registrant: BioNexus Gene Lab Corp. Address of Principal Executive Office: Unit A-28-7, Tower A, Menara UOA Bangsar, No. 5 |
|
| March 25, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2025. BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commission (IRS Employer of Inco |
|
| March 7, 2025 |
EXHIBIT 99.1 BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy March 7, 2025 – Kuala Lumpur, Malaysia – BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in the digital and healthcare space, has announced a strategic partnership with ML Tech to optimize the BGLC’s Ethereum-based growth strategies. ML Tech is an AI-driven wea |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2025. BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commission (IRS Employer of Incor |
|
| March 5, 2025 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper Kuala Lumpur, Malaysia – March 5, 2025 – BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in technology and healthcare, is pleased to announce that its Board of Directors has formally approved the Company’s new Eth |
|
| March 5, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 5, 2025 BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commission (IRS Employer of Incorp |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Def |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| February 14, 2025 |
Articles of Amendment filed with the Wyoming Secretary of State on February 11, 2025. EXHIBIT 3.6 |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (C |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (C |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-41750 BioNexus Gene Lab Corp. |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2024 PART I: REGISTRANT INFORMATION Full Name of Registrant: BioNexus Gene Lab Corp. Address of Principal Executive Office: Unit A-28-7, Tower A, Menara UOA Bangsar, No. |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (Co |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (Com |
|
| October 10, 2024 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (Com |
|
| September 25, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 25, 2024 (September 23, 2024). BioNexus Gene Lab Corp. (Exact name of Company as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction (Commiss |
|
| September 25, 2024 |
EXHIBIT 99.1 Press Release For Immediate Release BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd. Kuala Lumpur, Malaysia – September 25, 2024 – MRNA Scientific Sdn. Bhd. (“MRNA”), a subsidiary of BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), and Protech Builders Sdn. Bhd. (“Protech”), a leading mechanical and electrical |
|
| September 25, 2024 |
EXHIBIT 10.1 Teaming Agreement between MRNA Scientific Sdn. Bhd. and Protech Builders Sdn. Bhd. for Biogas Plant Development This Teaming Agreement (“Agreement”) is made on September 23, 2024 between: ● MRNA Scientific Sdn. Bhd. (“MRNA Scientific”, Co. 201501013741), a company incorporated in Malaysia, with its principal office at A-28-07 Menara UOA Bangsar, 5 Jalan Bangsar Utama 1, Kuala Lumpur 1 |
|
| September 18, 2024 |
EXHIBIT 99.1 BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd. KUALA LUMPUR, Malaysia, Sept. 14, 2024 (GLOBE NEWSWIRE) - BioNexus Gene Lab Corp.(Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce that its wholly owned subsidiary, MRNA Scientific Sdn. Bhd. (“MRNA Scientific”), |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 (September 14, 2024) BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdictio |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| September 12, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 (September 11, 2024) BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdictio |
|
| September 12, 2024 |
EXHIBIT 99.1 BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production Kuala Lumpur, Malaysia – September 11, 2024 – BioNexus Gene Lab Corp (Nasdaq: BGLC, the “Company”), an emerging Biotech & Chemicals company, is pleased to announce that its subsidiary, Chemrex Corporation Sdn. Bhd. (Chemrex), has invested approximate |
|
| September 12, 2024 |
EXHIBIT 99.2 BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions Kuala Lumpur, Malaysia – September 12, 2024 – BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce the signing |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| September 5, 2024 |
The Amended and Restated Bylaws EXHIBIT 3.1 BYLAWS OF BIO NEXUS GENE LAB CORP. ARTICLE I (Offices) Section 1.1. Principal Office. The principal office of the corporation shall be located at such place as the board shall designate. The corporation may have such other offices and places of business, either within or outside of Wyoming, as the board may designate or as the affairs of the corporation may require. Section 1.2. Regist |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 (September 4, 2024) BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction |
|
| August 28, 2024 |
EXHIBIT 99.1 BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd KUALA LUMPUR, August 27th, 2024 – BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and personalized medicine, is pleased to announce the successful co-investment by the Securities Commission of Malaysia under its Malaysia |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (Com |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other jurisdiction of incorporation) (Com |
|
| August 26, 2024 |
Shareholders Agreement and Term Sheet dated August 23, 2024 EXHIBIT 10.1 THIS SHAREHOLDERS AGREEMENT is made on 23rd August 2024 AMONGST (1) THE EXISTING SHAREHOLDERS whose names and particulars are as set out in Schedule 1; (2) THE CROWDFUNDING DIRECT SHAREHOLDERS whose names and particulars are set out in Schedule 2; (3) THE NOMINEE whose name and particulars are set out in Schedule 3; (“the Existing Shareholders, the Crowdfunding Direct Shareholders and |
|
| August 26, 2024 |
BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd EXHIBIT 99.1 BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd KUALA LUMPUR, August 26th, 2024 – BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and health technology, today announced the successful closing of its RM 1 million (Approx. USD228k) investment in Ascension Innovation Sdn Bhd (AISB), a pioneering Malaysi |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 001-41750 BioNexus Gene Lab Corp. |
|
| July 5, 2024 |
Amendment to the Service Contract between the Company and Mr. Su-Leng Tan Lee dated June 30, 2024 EXHIBIT 10.1 Date: June 30, 2024 Mr. Su-Leng Tan Lee C2-2-8 Megan Phoenix Off Jalan Cheras Kuala Lumpur, Malaysia Dear Mr. Tan Lee, Re: Amendment to Service Contract, recognition as Chief Executive Officer and Acting Chief Financial Officer We are pleased to extend this letter of offer to you, amending your current service contract dated August 15, 2023. This amendment recognizes your role as Chie |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2024 (March 26, 2024) BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 001-41750 35-2604830 (State or other j |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. 1 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. 1 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. 2 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. |
|
| May 23, 2024 |
May 23, 2024 Securities and Exchange Commission Division of Corporate Finance Washington DC 20549 Re: Comment Letter from Staff of Securities and Exchange Commission Dated May 6, 2022 BioNexus Gene Lab Corp. |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2024 BioNexus Gene Lab Corp. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commission File No.) |
|
| April 18, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Com |
|
| April 18, 2024 |
EXHIBIT 99.1 BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare FOR IMMEDIATE RELEASE Kuala Lumpur, Malaysia - April 18, 2024 — BioNexus Gene Lab Corporation (NASDAQ: BGLC), a global leader in genomic diagnostics and healthcare technology, announces a strategic investment by its wholly owned |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-269753 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| April 16, 2024 |
List of Subsidiaries of the Registrant EXHIBIT 21 Subsidiaries MRNA Scientific Sdn. Bhd., a Malaysian corporation Chemrex Corporation Sdn. Bhd., a Malaysian corporation |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Com |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 PART I: REGISTRANT INFORMATION Full Name of Registrant: BioNexus Gene Lab Corp. Address of Principal Executive Office: Unit 02, Level 10 Tower B, Avenue 3, The Vertic |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP. |
|
| February 29, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| January 26, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BIONEXUS GENE LAB CORP COMMON STOCK 090628207 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☐ Rule 13d-1(c) ☒ Rule 13d-1(d) * The remainder |
|
| January 17, 2024 |
Joint Filing Agreement, by and between the Reporting Persons. EX-99.1 2 bglcex991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the shares of common stock, no par value per share, of BioNexus Gene La |
|
| January 17, 2024 |
US0906282076 / BIONEXUS GENE LAB CORP / Lai Soo Kow - SC 13D Activist Investment SC 13D 1 bglcsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* BioNexus Gene Lab Corp. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 090628207 (CUSIP Number) Su-Leng (Sam) Tan Lee Unit 02, Level 10 Tower B, Avenue 3, The Vertical Business Suite II Bangsar Sou |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2023 PART I: REGISTRANT INFORMATION Full Name of Registrant: BioNexus Gene Lab Corp. Address of Principal Executive Office: Unit 02, Level 10 Tower B, Avenue 3, The Verti |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2023 BioNexus Gene Lab Corp. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commission File |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2023 BIONEXUS GENE LAB CORP. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or another jurisdiction of incorporation) (Commission Fil |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No.1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2023 BIONEXUS GENE LAB CORP. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or another jurisdiction of incorporation |
|
| October 17, 2023 |
BGLC / BioNexus Gene Lab Corp / Wong Chan Chong - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BioNexus Gene Lab Corp. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 090628207 (CUSIP Number) July 19, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2023 BIONEXUS GENE LAB CORP. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or another jurisdiction of incorporation) (Commission Fil |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 4, 2023 BIONEXUS GENE LAB CORP. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or another jurisdiction of incorporation) (Commission File |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 7, 2023 BIONEXUS GENE LAB CORP. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or another jurisdiction of incorporation) (Commission Fi |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification Of Late Filing SEC File Number 333-201360 ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 PART I: REGISTRANT INFORMATION Full Name of Registrant: BioNexus Gene Lab Corp. Address of Principal Executive Office: Unit 02, Level 10 Tower |
|
| July 24, 2023 |
EXHIBIT 99.1 BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market KUALA LUMPUR, Malaysia, July 20, 2023 (GlobeNewswire) - BioNexus Gene Lab Corp. (“BioNexus” or the “Company”), an emerging company in the business of selling chemical raw materials in the Southeast Asia region and the development of safe, effective, and non-invasive liqui |
|
| July 24, 2023 |
Form of Underwriter’s Warrants EXHIBIT 4.1 Underwriter’s Warrant THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES BY HIS, HER OR ITS ACCEPTANCE HEREOF, THAT SUCH HOLDER WILL NOT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS BEGINNING ON THE DATE OF COMMENCEMENT OF SALES OF THE OFFERING: (A) SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT OR THE SECURITIES ISSUABLE HEREUNDER TO ANYONE OTHER THAN OFFICERS |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2023 BioNexus Gene Lab Corp. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commission File No. |
|
| July 24, 2023 |
EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF BIONEXUS GENE LAB CORP. ARTICLE I (Offices) Section 1.1. Principal Office. The principal office of the corporation shall be located at such place as the board shall designate. The corporation may have such other offices and places of business, either within or outside of Wyoming, as the board may designate or as the affairs of the corporation may require. |
|
| July 24, 2023 |
EXHIBIT 99.2 BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market KUALA LUMPUR, Malaysia, July 24, 2023 (GlobeNewswire) - BioNexus Gene Lab Corp. (“BioNexus” or the “Company”) (Nasdaq: BGLC), an emerging company in the business of selling chemical raw materials in the Southeast Asia region a |
|
| July 24, 2023 |
EXHIBIT 1.1 UNDERWRITING AGREEMENT July 20, 2023 Network 1 Financial Securities, Inc. 2 Bridge Ave - Building 2 Suite 241 Red Bank, NJ 07701 Ladies and Gentlemen: Bionexus Gene Lab Corp., a Wyoming company (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Network 1 Financial Securities, Inc. (the “Underwriter”) an aggregate of 1 |
|
| July 21, 2023 |
BIONEXUS GENE LAB CORP. 1,250,000 Shares of Common Stock Filed pursuant to Rule 424(b)(4) Registration No. 333-269753 PROSPECTUS BIONEXUS GENE LAB CORP. 1,250,000 Shares of Common Stock We are offering up to an aggregate of 1,250,000 shares of our common stock, no par value per share, of BioNexus Gene Lab Corp, a Wyoming corporation, on a firm commitment basis. The initial public offering price of our common stock is $4.00 per share. Prior to this offer |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 20, 2023 BioNexus Gene Lab Corp. (Exact name of Company as specified in charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commission File No. |
|
| July 20, 2023 |
Article of Amendment dated March 29, 2023 EXHIBIT 3.1 |
|
| July 20, 2023 |
Article of Amendment dated June 5, 2023 EXHIBIT 3.2 |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 BioNexus Gene Lab Corp. (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No |
|
| July 17, 2023 |
Form of Representative’s Warrant EXHIBIT 4.2 Representative’s Warrant THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES BY HIS, HER OR ITS ACCEPTANCE HEREOF, THAT SUCH HOLDER WILL NOT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS BEGINNING ON THE DATE OF COMMENCEMENT OF SALES OF THE OFFERING: (A) SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT OR THE SECURITIES ISSUABLE HEREUNDER TO ANYONE OTHER THAN OFFIC |
|
| July 17, 2023 |
As filed with the Securities and Exchange Commission on July 14, 2023 As filed with the Securities and Exchange Commission on July 14, 2023 Registration No. |
|
| July 17, 2023 |
Form of Underwriting Agreement EXHIBIT 1.1 UNDERWRITING AGREEMENT [●], 2023 Network 1 Financial Securities, Inc. 2 Bridge Ave - Building 2 Suite 241 Red Bank, NJ 07701 As Representative of the several Underwriters named in Schedule I hereto Ladies and Gentlemen: Bionexus Gene Lab Corp., a Wyoming company (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to the s |
|
| July 17, 2023 |
EXHIBIT 99.2 AUDIT COMMITTEE CHARTER OF BIONEXUS GENE LAB CORP. I. Purpose The purposes of the Audit Committee (the “Audit Committee”) of the Board of Directors (“Board”) of BioNexus Gene Lab Corp., a Wyoming corporation (“Company”) are to assist the Board in monitoring: (1) the integrity of the annual, quarterly, and other financial statements of the Company, (2) the independent auditor’s qualifi |
|
| July 17, 2023 |
Compensation Committee Charter EXHIBIT 99.3 CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF BIONEXUS GENE LAB CORP. I. Purposes The Compensation Committee (the “Committee”) is appointed by the Board of Directors (the “Board”) of BioNexus Gene Lab Corp., a Wyoming corporation (the “Company”) for the purposes of, among other things, (a) discharging the Board’s responsibilities relating to the compensation of th |
|
| July 17, 2023 |
Code of Business Conduct and Ethics EXHIBIT 14.1 BIONEXUS GENE LAB CORP. Code of Ethics and Business Conduct 1. Introduction. 1.1 The Board of Directors (the “Board”) of BioNexus Gene Lab Corp. (the "Company") has adopted this Code of Ethics and Business Conduct (the "Code") in order to: (a) promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest; (b) promote full, fair, accurat |
|
| July 17, 2023 |
Share Exchange Agreement between BioNexus and Chemrex EXHIBIT 10.1 |
|
| July 17, 2023 |
EXHIBIT 99.4 NOMINATION COMMITTEE CHARTER OF BIONEXUS GENE LAB CORP. The responsibilities and powers of the Nominating Committee (the “Nominating Committee”) of the Board of Directors (“Board”) of BioNexus Gene Lab Corp., a Wyoming corporation (the “Company”), as delegated by the Board, are set forth in this charter. Whenever the Nominating Committee takes an action, it shall exercise its independ |
|
| July 5, 2023 |
Registrant’s Specimen Certificate for Common Stock EXHIBIT 4.1 |
|
| July 5, 2023 |
Certificate of Amendment filed with the Secretary of the State of Wyoming on June 7, 2017 EXHIBIT 3.3 |
|
| July 5, 2023 |
Employment Agreement with Yee Meng Wong EXHIBIT 10.3 Bionexus Gene Lab Corporation Bionexus Gene Lab Sdn Bhd 203 S Main Street STE 3000, Wyoming 82801, USA Tel: +60122126512 10-2, Tower B, Vertical Business Suite II, Avenue 3, Bangsar South City, 8 Jalan Kerinchi 59200 Kuala Lumpur, Malaysia Tel: 03-74940760 Date: August 2, 2022 Ms. Yee Meng Wong, PhD 55, Jalan Prai, Off Jalan Meru Klang, Selangor, Malaysia 41050 Dear Dr. Wong President |
|
| July 5, 2023 |
Employment Agreement with Wei Li Leong EXHIBIT 10.5 Bionexus Gene Lab Corporation Bionexus Gene Lab Sdn Bhd 203 S Main Street STE 3000, Wyoming 82801, USA Tel: +60122126512 10-2, Tower B, Vertical Business Suite, Avenue 3, Bangsar South City, 8 Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia Tel: 03-74940760 This Executive Employment Agreement (the “Agreement”) is made and entered into as of the 19th day of June, 2017 and will be effectiv |
|
| July 5, 2023 |
Certificate of Amendment filed with the Secretary of the State of Wyoming on March 29, 2023 EXHIBIT 3.4 |
|
| July 5, 2023 |
Director Offer Letter by and between the Registrant and Chee Keong Yap EXHIBIT 10.11 BioNexus Gene Lab Corp. Unit 02, Level 10, Tower B, Vertical Business Suite Bangsar South, 8 Jalan Kerinchi 59200 Kuala Lumpur Malaysia October 1, 2022 Re: Director Offer Letter – Chee Keong Yap Dear Mr. Chee Keong Yap: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background an |
|
| July 5, 2023 |
As filed with the Securities and Exchange Commission on July 3, 2023 As filed with the Securities and Exchange Commission on July 3, 2023 Registration No. |
|
| July 5, 2023 |
Director Offer Letter by and between the Registrant and Teng Fook Fong EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) BioNexus Gene Lab Corp. |
|
| July 5, 2023 |
Certificate of Amendment filed with the Secretary of the State of Wyoming on June 5, 2023 EXHIBIT 3.5 |
|
| July 5, 2023 |
Director Offer Letter by and between the Registrant and Chai Ping Lin EXHIBIT 10.8 BioNexus Gene Lab Corp. Unit 02, Level 10, Tower B, Vertical Business Suite Bangsar South, 8 Jalan Kerinchi 59200 Kuala Lumpur Malaysia January 16, 2023 Re: Director Offer Letter – Chai Ping Lin Dear Ms. Chai Ping Lin: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background and |
|
| July 5, 2023 |
Employment Agreement with Yeat Min Fong EXHIBIT 10.2 Bionexus Gene Lab Corporation 203 S Main Street STE 3000, Wyoming 82801 USA Branch: 10-2 Tower B, Vertical Business Suite, Bangsar South, 8 Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia Tel: +60182218762, +6037494076 Date: August 2, 2022 Dr. Yeat Min Fong Lot 16.08, 1 Powerhouse, Persiaran Bandar Utama 47800 Petaling Jaya, Selangor, Malaysia Dear Dr. Fong Chairman/Board Member Thank yo |
|
| July 5, 2023 |
Director Offer Letter by and between the Registrant and Chak Hua Yew EXHIBIT 10.9 BioNexus Gene Lab Corp. Unit 02, Level 10, Tower B, Vertical Business Suite Bangsar South, 8 Jalan Kerinchi 59200 Kuala Lumpur Malaysia October 1, 2022 Re: Director Offer Letter – Chak Hua Yew Dear Mr. Chak Hua Yew: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background and exp |
|
| July 5, 2023 |
Employment Agreement with Sook Keng Yeoh EXHIBIT 10.4 Bionexus Gene Lab Corporation Bionexus Gene Lab Sdn Bhd 203 S Main Street STE 3000, Wyoming 82801, USA Tel: +60122126512 10-2, Tower B, Vertical Business Suite II, Avenue 3, Bangsar South City, 8 Jalan Kerinchi 59200 Kuala Lumpur, Malaysia Tel: 03-74940760 Date: July 29, 2022 Mr. Sook Keng Yeoh 40 Jalan TR 3/1, Tropicana Petaling Jaya 47410 Selangor, Malaysia Dear Mr. Yeoh Chief Execu |
|
| July 5, 2023 |
Director Offer Letter by and between the Registrant and Teng Fook Fong EXHIBIT 10.7 BioNexus Gene Lab Corp. Unit 02, Level 10, Tower B, Vertical Business Suite Bangsar South, 8 Jalan Kerinchi 59200 Kuala Lumpur Malaysia October 1, 2022 Re: Director Offer Letter – Teng Fook Fong Dear Mr. Teng Fook Fong: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background and |
|
| July 5, 2023 |
Employment Agreement with Liong Tai Tan EXHIBIT 10.6 Bionexus Gene Lab Corporation Bionexus Gene Lab Sdn Bhd 203 S Main Street STE 3000, Wyoming 82801, USA Tel: +60122126512 10-2, Tower B, Vertical Business Suite II, Avenue 3, Bangsar South City, 8 Jalan Kerinchi 59200 Kuala Lumpur, Malaysia Tel: 03-74940760 Date: Nov 27, 2020 Mr Liong Tai Tan 56 Jalan Bakau, Kepong Baru Kuala Lumpur Malaysia Dear Mr Tan Chief Operating Officer/Board Me |
|
| July 5, 2023 |
Director Offer Letter by and between the Registrant and Boon Teong Teoh EXHIBIT 10.10 BioNexus Gene Lab Corp. Unit 02, Level 10, Tower B, Vertical Business Suite Bangsar South, 8 Jalan Kerinchi 59200 Kuala Lumpur Malaysia January 16, 2023 Re: Director Offer Letter – Boon Teong Teoh Dear Mr. Boon Teong Teoh: BioNexus Gene Lab Corp., a Wyoming corporation (the “Company” or “we”), is pleased to offer you a position as a Director of the Company. We believe your background |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement BioNexus Gene Lab Corp. (Name of Reg |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP. |
|
| May 9, 2023 |
As filed with the Securities and Exchange Commission on May 9, 2023 As filed with the Securities and Exchange Commission on May 9, 2023 Registration No. |
|
| May 9, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) BioNexus Gene Lab Corp. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-269753 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement BioNexus Gene Lab Corp. (Name of Reg |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement BioNexus Gene Lab Corp. (Name of Reg |
|
| February 14, 2023 |
List of Subsidiaries of the Registrant EX-21.1 2 bionex211.htm SUBSIDIARIES EXHIBIT 21.1 Subsidiaries BioNexus Gene Lab Sdn. Bhd., a Malaysian corporation Chemrex Corporation Sdn. Bhd., a Malaysian corporation |
|
| February 14, 2023 |
As filed with the Securities and Exchange Commission on February 14, 2023 As filed with the Securities and Exchange Commission on February 14, 2023 Registration No. |
|
| February 14, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) BioNexus Gene Lab Corp. |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Bionexus Gene Lab Corp. (Name of Reg |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP. |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP. |
|
| August 15, 2022 |
Securities Purchase Agreement between the Company and Kevin Wong EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT, made as of this 12th day of April 2022, by and between Keith Wong, (“Purchaser”) with an address located at 7222 E. Doubletree Ranch Rd, Unit 300, Scottsdale, Arizona 85258, USA and Bionexus Gene Lab Corp (“Seller”) with an address located at Tower B, Vertical Business Suite 10-2, No. 8, Jalan Kerinchi, Bangsar South, 59200, |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2022 Bionexus Gene Lab Corp (Exact name of Company as specified in charter) Wyoming 001-37513 47-3709051 (State or other jurisdiction of incorporation) (Commission File No.) |
|
| August 15, 2022 |
EX-10.2 3 bionex102.htm CONSULTING AGREEMENT EXHIBIT 10.2 CONSULTING AGREEMENT This Consulting Agreement (the "Agreement") is made and entered into as of Apr 15, 2022 (the "Effective Date"), between BIONEXUS GENE LAB CORP (the "Company"), a corporation registered in Wyoming, located at Tower B, Vertical Business Suite 10-2, No. 8, Jalan Kerinchi, Bangsar South, 59200, Kuala Lumpur, and Keith Wong, |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP. |
|
| April 6, 2022 |
EX-21 2 bionex21.htm SUBSIDIARIES EXHIBIT 21 Subsidiaries Bionexus Gene Lab Sdn. Bhd., a Malaysian corporation Chemrex Corporation Sdn. Bhd., a Malaysian corporation |
|
| April 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| April 1, 2022 |
NT 10-K 1 bionnt10k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 333-229399 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP. |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP. |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 333-229399 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| March 30, 2021 |
EXHIBIT 21 Subsidiaries Bionexus Gene Lab Sdn. Bhd., a Malaysian corporation Chemrex Corporation Sdn. Bhd., a Malaysian corporation |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| March 11, 2021 |
EXHIBIT 99.1 CHEMREX CORPORATION SDN. BHD. INDEX TO THE AUDITED FINANCIAL STATEMENTS Years Ended December 31, 2019 and 2018 TABLE OF CONTENTS Page Report of Independent Registered Public Accounting Firm 2 Balance Sheets 3 Statements of Operations and Other Comprehensive Income (Loss) 4 Statements of Stockholders’ Equity 5 Statements of Cash Flows 6 Notes to the Financial Statements 7- 13 1 REPORT |
|
| March 11, 2021 |
EX-99.2 3 bionex992.htm UNAUDITED FINANCIAL STATEMENTS EXHIBIT 99.2 CHEMREX CORPORATION SDN. BHD. INDEX TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS 9 MONTHS ENDED SEPTEMBER 30, 2020 TABLE OF CONTENTS Page Balance Sheets 2 Statements of Operations and Other Comprehensive Income/(Loss) 3 Statements of Stockholders’ Equity 4 Statements of Cash Flows 5 Notes to the Unaudited Financial Statements 6-1 |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 31, 2020 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation or organ |
|
| March 11, 2021 |
EX-99.3 4 bionex993.htm UNAUDITED PRO FORMA FINANCIAL INFORMATION EXHIBIT 99.3 BIONEXUS GENE LAB CORP. UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET AS OF SEPTEMBER 30, 2020 Historical Pro Forma Adjustments Pro Forma BGLC CCSB (Note 3) Combined Assets Current assets: Cash and cash equivalents $ 687,203 $ 1,502,869 $ - $ 2,190,072 Other receivables and deposits 13,847 7,154 - 21,001 Trade re |
|
| January 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2020 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commissi |
|
| January 7, 2021 |
EX-3.1 2 bionex31.htm CERTIFICATE OF INCORPORATION EXHIBIT 3.1(d) 1 2 |
|
| December 30, 2020 |
EXHIBIT 10.5 SHARE EXCHANGE AGREEMENT This Agreement ("Agreement") is made and entered into this the 24th day of December 2020 by and between BioNexus Gene Lab Corp, a Wyoming company (the "BioNexus"), and Chemrex Corporation Sdn. Bhd., a Malaysian company ("Chemrex"), and the shareholders of the Chemrex identified on the signatory page of this Agreement (the "Chemrex Shareholders"). * W I T N E S |
|
| December 30, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 bion8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 24, 2020 BIONEXUS GENE LAB CORP . (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction |
|
| December 22, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2020 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commissi |
|
| December 22, 2020 |
EXHIBIT 99.1 RNA AS A SCREENING TOOL AND BIOMARKER FOR DISEASE: A PARADIGM SHIFT IN MEDICAL RISK STRATIFICATION DR STEPHEN PONNAMPALAM 1 Characteristics of an ideal biomarker DNA vs RNA as biomarker for risk stratification Sentinel principle: its applications for disease detection Epidemiology of disease mortality in Malaysia with a focus on cancer Current biomarkers: drawbacks ColonSentry: a trai |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2020 BIONEXUS GENE LAB CORP . (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commiss |
|
| November 9, 2020 |
Quarterly Report - FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. |
|
| November 3, 2020 |
10-Q 1 bion10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission Fil |
|
| October 8, 2020 | ||
| October 8, 2020 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2020 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commission |
|
| August 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| March 31, 2020 |
EXHIBIT 21 Subsidiaries Bionexus Gene Lab Sdn. Bhd., a Malaysian corporation |
|
| March 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction ofIncorporation or Organization) (I. |
|
| March 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 333-229399 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2019 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| November 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ¨ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| November 14, 2019 |
EXHIBIT 10.5 |
|
| October 15, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2019 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 333-229399 35-2604830 (State or other jurisdiction of incorporation) (Commission |
|
| October 15, 2019 |
EXHIBIT 10.4 BIONEXUS GENE LAB CORPORATION Stock Grant Agreement Effective Date: October 1, 2019 Grantee: Chan Chong Wong ? Chief Executive Officer (?Grantee?) Name Title Number of shares of Common Stock subject to Grant: 5,000,000 Definitions As used herein the following words and phrases shall have the meanings ascribed thereto. ?Business Relationship with the Company? means the officer/employer |
|
| August 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ? TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| May 15, 2019 |
Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-229399 BIONEXUS GENE LAB CORP (Exact name of registrant as specified in its charter) Wyoming 35-2604830 (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| April 2, 2019 |
BIONEXUS GENE LAB CORP. Level 8, Tower 8, Avenue 5, The Horizon Bangar South No. 8 Jalan Kerinchi 59200 Kuala Lumpur Malaysia April 2, 2016 Via EDGAR SECURITIES AND EXCHANGE COMMISSION Securities and Exchange Commission Attn: Mr. Ruairi Regan Division of Corporate Finance Washington DC 20549 Re: BioNexus Gene Lab Corporation File No. 333-229399 Dear Mr. Regan: BioNexus Gene Lab Corporation hereby |
|
| April 2, 2019 |
CORRESP 1 filename1.htm BIONEXUS GENE LAB CORP. Level 8, Tower 8, Avenue 5, The Horizon Bangar South No. 8 Jalan Kerinchi 59200 Kuala Lumpur Malaysia April 2, 2019 Via EDGAR SECURITIES AND EXCHANGE COMMISSION Securities and Exchange Commission Attn: Mr. Ruairi Regan Division of Corporate Finance Washington DC 20549 Re: BioNexus Gene Lab Corporation File No. 333-229399 Dear Mr. Regan: BioNexus Gene |
|
| March 27, 2019 |
March 26, 2019 Securities and Exchange Commission Attn: Mr. Ruairi Regan Division of Corporate Finance Washington DC 20549 Re: BioNexus Gene Lab Corporation Amendment No. 1 to Registration Statement on Form S-1 Filed February 25, 2019 File No. 333-229399 Dear Mr. Regan: On behalf of our client, BioNexus Gene Lab Corporation, a Wyoming corporation (the “Company”), we are filing herewith an Amendmen |
|
| March 27, 2019 |
S-1/A 1 a-2vedgar2.htm As filed with the Securities and Exchange Commission on March 27 , 2019 Registration No. 333-229399 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 807101 35-2604830 (State or other jur |
|
| February 25, 2019 |
As filed with the Securities and Exchange Commission on February , 2019 Registration No. |
|
| February 25, 2019 |
Converted by EDGARwiz February 25, 2019 Securities and Exchange Commission Attn: Mr. |
|
| January 29, 2019 | ||
| January 29, 2019 | ||
| January 29, 2019 |
Converted by EDGARwiz BYLAWS OF BIO NEXUS GENE LAB CORP. ARTICLE I (Offices) Section 1.1. Principal Office. The principal office of the corporation shall be located at such place as the board shall designate. The corporation may have such other offices and places of business, either within or outside of Wyoming, as the board may designate or as the affairs of the corporation may require. Section 1 |
|
| January 29, 2019 |
LIEW CHOONG-CHIN 81 Millersgrove Dr. Toronto M2R 3S1 ON Canada Date: 15.2.2018 The Board of Directors Bionexus Gene Lab SDN. BHD. 20-12 Camellia,5 Jalan Kerinchi . Bangsar South Kuala Lumpur Dear Sirs, Re: WAIVER OF LIABILITIES I, Liew Choong-Chin (Passport No. GK429314), a shareholder of Bionexus Gene Lab Sdn Bhd, hereby confirmed and agreed on this date to waive all the money owing by Bionexus G |
|
| January 29, 2019 |
S-1 1 final1-23-19vedgar4.htm As filed with the Securities and Exchange Commission on , 2019 Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONEXUS GENE LAB CORP. (Exact name of registrant as specified in its charter) Wyoming 807101 35-2604830 (State or other jurisdiction of incorporation or |
|
| January 29, 2019 | ||
| January 29, 2019 |
Articles of Amendment of Registrant(1) Converted by EDGARwiz |
|
| January 29, 2019 |
Articles of Incorporation of the Registrant, as currently in effect Converted by EDGARwiz Wyoming Secretary of State 2020 Carey Avenue Suite 700 Cheyenne, WY 82002-0020 Ph. |
